Compare TLSA & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLSA | MBOT |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 126.9M |
| IPO Year | 2017 | 2000 |
| Metric | TLSA | MBOT |
|---|---|---|
| Price | $1.07 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.1M | 753.0K |
| Earning Date | 05-04-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,887.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $119.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $1.44 |
| 52 Week High | $2.35 | $4.09 |
| Indicator | TLSA | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 39.12 |
| Support Level | $0.90 | $1.44 |
| Resistance Level | $1.17 | $2.21 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 56.84 | 13.46 |
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.